Effect of community-based distribution of misoprostol on facility delivery: a scoping review.
INTRODUCTION
Community distribution of misoprostol to pregnant women in advance of labor is one of the compelling strategies for preventing postpartum hemorrhage. Concerns have been reported that misoprostol distribution could reduce facility delivery or lead to misuse of the medication. This scoping review was conducted to synthesize the evidence on the effect of community-based misoprostol distribution on rates of facility delivery, and to assess the frequency of mothers taking distributed misoprostol before delivery, and any harmful outcomes of such misuse.


METHODS
We included peer-reviewed articles on misoprostol implementation from PubMed, Cochrane Review Library, Popline, and Google Scholars. Narrative synthesis was used to analyze and interpret the findings, in which quantitative and qualitative syntheses are integrated.


RESULTS
Three qualitative studies, seven observational studies, and four experimental or quasi-experimental studies were included in this study. All before-after household surveys reported increased delivery coverage after the intervention: ranging from 4 to 46 percentage points at the end of the intervention when compared to the baseline. The pooled analysis of experimental and quasi-experimental studies involving 7564 women from four studies revealed that there was no significant difference in rates of facility delivery among the misoprostol and control groups [OR 1.011; 95% CI: 0.906-1.129]. A qualitative study among health professionals also indicated that community distribution of misoprostol for the prevention of postpartum hemorrhage is acceptable to community members and stakeholders and it is a feasible interim solution until access to facility birth increases. In the community-based distribution of misoprostol programs, self-administration of misoprostol by pregnant women before delivery was reported in less than 2% of women, among seven studies involving 11,108 mothers. Evidence also shows that most women who used misoprostol pills, used them as instructed. No adverse outcomes from misuse in either of the studies reviewed.


CONCLUSIONS
The claim that community-based distribution of misoprostol would divert women who would have otherwise had institutional deliveries to have home deliveries and promote misuse of the medication are not supported with evidence. Therefore, community-based distribution of misoprostol can be an appropriate strategy for reducing maternal deaths which occur due to postpartum hemorrhages, especially in resource-limited settings.
['Tiruneh|Gizachew Tadele|GT|http://orcid.org/0000-0002-5842-9518', 'Yakob|Bereket|B|', 'Ayele|Wubegzier Mekonnen|WM|', 'Yigzaw|Muluneh|M|', 'Roro|Meselech Assegid|MA|', 'Medhanyi|Araya Abrha|AA|', 'Hailu|Etenesh Gebreyohannes|EG|', 'Bayou|Yibeltal Tebekaw|YT|']
D003695:Delivery of Health Care D005260:Female D014943:Global Health D006801:Humans D015994:Incidence D007743:Labor, Obstetric D016595:Misoprostol D010120:Oxytocics D006473:Postpartum Hemorrhage D011247:Pregnancy D012307:Risk Factors D015996:Survival Rate
Community-based distribution Misoprostol Facility delivery Diversion of facility birth